Immutep (ASX:IMM) received roughly AU$3.6 million in research and development-related tax incentives from the French government, according to a Tuesday filing with the Australian bourse.
The ASX-listed biotechnology company received the payment through its subsidiary, Immutep SAS. Under the French government's Research Tax Credit scheme, French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure, the filing stated.
Immutep said it will use the funds for the global clinical development of eftilagimod alpha and IMP761.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.